Insider buying last 90 days
No open-market insider purchases were filed for CRSP in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
CRISPR Therapeutics presented positive Phase 1b data for CTX310, its gene editing therapy, showing reductions in ANGPTL3 and triglycerides in patients with severe hypertriglyceridemia at the American Heart Association Scientific Sessions 2026. The company also updated on zugo-cel, its gene-edited CAR-T therapy, for refractory rheumatologic autoimmune diseases, citing positive Phase 1 responses in systemic sclerosis (83% at Month 3) and idiopathic inflammatory myopathy (100% improved). Alongside this clinical news, analysts have trimmed near-term revenue forecasts for 2027 to US$133m while raising loss per share estimates to US$3.57, following a recent quarterly report that missed revenue expectations by 24% and showed a 15% larger loss per share than anticipated.
CRSP closed at $50.04, down 0.1%, sitting between its 50-day average of $53.12 and 200-day average of $52.73. The stock's one-month return stands at -6.3%, with six-month and one-year returns of -7.4% and -11.6%. The GekkoIndex reads 60.2, placing it in the Accumulation zone, and the current price sits 18.9% below Gekko Fair Value of $61.70.
The next earnings date is 11 February 2027, 93 days out, placing it beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears within the respective 90-day and 30-day windows, though recent filings include a Form 144 and a Form 4 from the Chief Technical Officer, along with a proposed officer sale of 79,393 shares. Seasonality over five years shows an average 20-trading-day return of 1.7%, with gains in 3 of those years. Analyst sentiment includes 8 buy and 6 hold ratings among 14 firms, with a consensus target of $74.33.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
CRISPR Therapeutics scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $42.24 is below the 50-day ($52.09) and 200-day ($52.53) averages, and the 50-day is below the 200-day.
See the chart71.1, Buying
Reading 71.1 is in the Buying zone.
See the GekkoIndex34.3% below
Price is 34.3% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 88 days
Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.
See earnings−3.6% on average
From this point in the calendar, the next 20 trading days averaged −3.6% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
CRISPR Therapeutics closed at $42.24 on Nov 13, 2026, −19.1% over the past year, inside a 52-week range of $41.75 to $63.45.
Use the left and right arrow keys to read daily values.
Put CRSP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
CRISPR Therapeutics works on gene-editing treatments for serious illnesses, built around its CRISPR/Cas9 technology, which allows targeted changes to genetic material. Its research spans blood disorders, cancer, regenerative medicine and rare diseases, and it is best known for CTX001, a gene-edited therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease that works by editing a patient's own stem cells to raise fetal hemoglobin levels.
Beyond CTX001, the company is developing donor-derived CAR-T candidates such as CTX110, CTX120 and CTX130, aimed at different blood cancers and solid tumors, along with VCTX210, a stem cell-based candidate for type 1 diabetes, and additional in vivo editing programs targeting the liver, lungs, muscles and nervous system. It carries out this work partly through partnerships, including ones with Bayer Healthcare, Vertex Pharmaceuticals, ViaCyte, Nkarta and Capsida Biotherapeutics.
CRISPR Therapeutics was founded in 2013 and is headquartered in Zug, Switzerland. Its shares are listed on the NASDAQ under the ticker CRSP.
CRISPR Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.1, in the Buying zone, up 10.2 points over five sessions.
Up 10.2 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 37 | +0.2% | +3.4% | ||
| Accumulation | 272 | +1.4% | +3.4% | ||
| Neutral | 344 | −0.9% | −2.3% | ||
| Distribution | 47 | +0.4% | 0.0% | ||
| Selling | 2 | Too few readings yet | |||
Average CRSP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
CRISPR Therapeutics trades 34.3% below Gekko Fair Value of $64.26, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what CRISPR Therapeutics shares are worth, recalculated every trading day.
$64.26
Gekko Fair Value, Nov 14, 2026
34.3% Undervalued
At the end of Aug 2026 the price was 24.7% below the estimate.
No open-market insider purchases were filed for CRISPR Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CRSP in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CRSP were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
CRISPR Therapeutics has been buying back its own shares.
From company filings.
CRISPR Therapeutics reports on Feb 11, 2027, after the close (88 days away), and beat the EPS estimate in 3 of its last 8 reports.
Feb 11, 2027
Expected after the close, 88 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | −$1.15 est −$1.04 | $12.67M est $14.75M | −2.8% |
| Aug 3, 2026 | −$0.94 est −$1.19 | $10.18M est $7.45M | +10.6% |
| May 4, 2026 | −$1.28 est −$1.23 | $1.46M est $6.06M | +1.5% |
| Feb 12, 2026 | −$1.37 est −$1.17 | $864K est $4.72M | +9.8% |
| Nov 10, 2025 | −$1.17 est −$1.31 | $889K est $9.12M | +0.2% |
| Aug 5, 2025 | −$2.40 est −$1.47 | $892K est $6.14M | −5.5% |
| May 6, 2025 | −$1.58 est −$1.27 | $865K est $5.96M | −9.0% |
| Feb 11, 2025 | −$0.44 est −$1.19 | $35.00M est $8.06M | +9.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for CRISPR Therapeutics is $85.42, +102.2% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Piper Sandler | $110 | +160.4% |
| Nov 9 | Needham | $82 | +94.1% |
| Nov 9 | H.C. Wainwright | $80 | +89.4% |
| Nov 9 | J.P. Morgan | $67 | +58.6% |
| Nov 8 | Citi | $90 | +113.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, CRISPR Therapeutics averaged −3.6% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.1% | 1 of 5 |
| Next 10 trading days | +1.8% | 2 of 5 |
| Next 15 trading days | +2.9% | 2 of 5 |
| Next 20 trading days | −3.6% | 2 of 5 |
| Next 30 trading days | −9.3% | 2 of 5 |
For scale, CRSP’s typical 20-trading-day move in either direction is about 10.3%.
CRISPR Therapeutics’s market cap is $4.10B and revenue of $25.17M over the last twelve months.
Coverage of CRISPR Therapeutics this week reads neutral: 6 positive, 7 neutral and 3 negative headlines.
CRISPR Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
CRISPR Therapeutics’s market cap is $4.10B at the Nov 13, 2026 close of $42.24, with 97.00M shares outstanding.
The consensus analyst 12-month price target for CRISPR Therapeutics is $85.42, +102.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate CRISPR Therapeutics is undervalued: the Nov 13, 2026 close of $42.24 is 34.3% below Gekko Fair Value of $64.26. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
CRISPR Therapeutics is expected to report on Feb 11, 2027, after the market closes (88 days away). Analysts expect earnings of −$1.17 per share on revenue of $11.34M. CRISPR Therapeutics beat the earnings estimate in 3 of its last 8 reports, moving 6.2% on average across the report.
CRISPR Therapeutics’s 52-week high is $63.45 and its 52-week low is $41.75; it closed at $42.24 on Nov 13, 2026, −19.1% over the past year. Over the last five years the shares peaked at $91.10 on Feb 22, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.